Quick answer
What is Cagrilintide?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk. No qualified clinical reviewer. How this site works
Cagrilintide is a peptide, grouped on this site under Amylin and amylin receptor agonists, and the 12 research records kept here are 2 from studies in rats or mice, 7 from trials in people and 3 that do not state what kind of study it is.
The literature search returned 103 records. This site keeps 12 of them, which is 12 per cent of what came back.
What it is
This site puts it in the Amylin and amylin receptor agonists group.
A long-acting amylin analogue reported in the retrieved records to act at amylin and calcitonin family receptors, with brain amylin receptors 1 and 3 named in a 2025 record.[1, 2]
Stated in the titles of the cited 2021 Journal of Medicinal Chemistry and 2025 EBioMedicine papers.
What kind of records
Several of the records kept here are trials in people.
That sentence is produced by counting, not by reading. What was counted: 7 of 12 indexed records are interventional human trials by their own assigned publication type.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 91 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of medicinal chemistry (2021). pmid:34288673
- Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. EBioMedicine (2025). pmid:40609154